TW202327653A - 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 - Google Patents
用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 Download PDFInfo
- Publication number
- TW202327653A TW202327653A TW111144466A TW111144466A TW202327653A TW 202327653 A TW202327653 A TW 202327653A TW 111144466 A TW111144466 A TW 111144466A TW 111144466 A TW111144466 A TW 111144466A TW 202327653 A TW202327653 A TW 202327653A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- chain variable
- variable region
- sequence
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/US16/37708 | 2016-06-15 | ||
| PCT/US2016/037708 WO2017217985A1 (en) | 2016-06-15 | 2016-06-15 | Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202327653A true TW202327653A (zh) | 2023-07-16 |
Family
ID=56292925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111144466A TW202327653A (zh) | 2016-06-15 | 2017-06-15 | 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 |
| TW106119998A TW201803591A (zh) | 2016-06-15 | 2017-06-15 | 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106119998A TW201803591A (zh) | 2016-06-15 | 2017-06-15 | 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3472202A1 (pt) |
| JP (2) | JP2019521981A (pt) |
| CN (1) | CN109311972A (pt) |
| AR (1) | AR108790A1 (pt) |
| AU (2) | AU2016411388A1 (pt) |
| BR (1) | BR112018076287A2 (pt) |
| CA (1) | CA3020894A1 (pt) |
| EA (1) | EA201892707A1 (pt) |
| MX (2) | MX2018015363A (pt) |
| TW (2) | TW202327653A (pt) |
| WO (1) | WO2017217985A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201991514A1 (ru) | 2016-12-21 | 2019-12-30 | Сефалон, Инк. | Антитела, которые специфически связываются с ил-15, и их применение |
| EP3873521A2 (en) * | 2018-10-31 | 2021-09-08 | Tiziana Life Sciences PLC | Composition and methods of treating inflammatory and autoimmune diseases |
| MX2024001934A (es) | 2021-08-12 | 2024-03-04 | Amgen Inc | Formulaciones de anticuerpos. |
| WO2024028448A1 (en) | 2022-08-04 | 2024-02-08 | Calypso Biotech Sa | Il-15 inhibitors useful for the treatment of atopic dermatitis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| EA015897B1 (ru) * | 2003-02-26 | 2011-12-30 | Генмаб А/С | Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие |
| JP2012516153A (ja) * | 2009-01-29 | 2012-07-19 | アボット・ラボラトリーズ | Ｉｌ−１結合タンパク質 |
| WO2011031986A1 (en) * | 2009-09-10 | 2011-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health | Assays for soluble il-15 receptor alpha |
| EP2963057A1 (en) * | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
-
2016
- 2016-06-15 JP JP2018565345A patent/JP2019521981A/ja active Pending
- 2016-06-15 CA CA3020894A patent/CA3020894A1/en active Pending
- 2016-06-15 EA EA201892707A patent/EA201892707A1/ru unknown
- 2016-06-15 WO PCT/US2016/037708 patent/WO2017217985A1/en unknown
- 2016-06-15 EP EP16733804.5A patent/EP3472202A1/en active Pending
- 2016-06-15 AU AU2016411388A patent/AU2016411388A1/en not_active Abandoned
- 2016-06-15 CN CN201680086774.8A patent/CN109311972A/zh active Pending
- 2016-06-15 MX MX2018015363A patent/MX2018015363A/es unknown
- 2016-06-15 BR BR112018076287-3A patent/BR112018076287A2/pt active Search and Examination
- 2016-06-15 MX MX2024001374A patent/MX2024001374A/es unknown
-
2017
- 2017-06-15 AR ARP170101652A patent/AR108790A1/es unknown
- 2017-06-15 TW TW111144466A patent/TW202327653A/zh unknown
- 2017-06-15 TW TW106119998A patent/TW201803591A/zh unknown
-
2021
- 2021-09-24 JP JP2021155175A patent/JP2022001577A/ja active Pending
-
2024
- 2024-07-31 AU AU2024205264A patent/AU2024205264A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109311972A (zh) | 2019-02-05 |
| EP3472202A1 (en) | 2019-04-24 |
| AU2016411388A1 (en) | 2018-11-08 |
| BR112018076287A2 (pt) | 2019-03-26 |
| JP2022001577A (ja) | 2022-01-06 |
| MX2024001374A (es) | 2024-02-27 |
| MX2018015363A (es) | 2019-04-15 |
| WO2017217985A1 (en) | 2017-12-21 |
| AU2024205264A1 (en) | 2024-08-22 |
| EA201892707A1 (ru) | 2019-05-31 |
| CA3020894A1 (en) | 2017-12-21 |
| JP2019521981A (ja) | 2019-08-08 |
| TW201803591A (zh) | 2018-02-01 |
| AR108790A1 (es) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230287094A1 (en) | Tgf-beta 3 specific antibodies and methods and uses thereof | |
| JP2023039448A (ja) | がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ | |
| US20190328762A1 (en) | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment | |
| JP7389077B2 (ja) | インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 | |
| JP7459058B2 (ja) | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 | |
| TW200932268A (en) | Binding molecules to the human OX40 receptor | |
| TW201726170A (zh) | Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途 | |
| TW202327653A (zh) | 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 | |
| EP3191120B1 (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| JP7455749B2 (ja) | 頭頸部癌の処置 | |
| JP2022532229A (ja) | 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用 | |
| EP3145543A2 (en) | Treatment of eosinophil or mast cell related disorders | |
| CN112040980A (zh) | 用于治疗代谢功能障碍或低瘦蛋白血症的瘦蛋白受体激动剂抗体 | |
| KR20220042067A (ko) | Gm-csf 길항제를 사용한 암의 치료 | |
| US20230312701A1 (en) | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease | |
| KR20210131312A (ko) | 인간 cd137에 결합하는 항체의 제제 및 이의 용도 | |
| KR20210088640A (ko) | 암을 치료하기 위한 항-lag3 항체의 투여 요법 및 항-pd-1 항체와의 조합 요법 | |
| US20240010729A1 (en) | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer | |
| US20230149543A1 (en) | Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein | |
| WO2021190582A1 (zh) | 一种抗ox40抗体药物组合物及其用途 | |
| TW202237081A (zh) | 抗體及紫杉烷合併療法 | |
| JP2023512181A (ja) | 癌を治療するためのｅｇｆｒ阻害剤とｒｏｒ１阻害剤の組み合わせ |